![paragon trial paragon trial](https://www.juniper.net/documentation/us/en/software/active-assurance3.0.0/rest-api-orchestration/images/netrounds-overview.png)
![paragon trial paragon trial](https://i0.wp.com/macwarez.net/wp-content/uploads/2017/11/Paragon-NTFS-15.1.26-Crack-Trial-Reset-Mac-OS.png)
“We look forward to presenting and discussing the data from PARAGON-HF, which should inform our understanding and treatment of HFpEF, at the ESC Congress 2019,” said Scott Solomon, M.D., Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, and PARAGON-HF Executive Committee Co-Chair. We embarked upon the landmark Phase III PARAGON-HF trial to determine whether sacubitril/valsartan could have a meaningful impact on the treatment of HFpEF, as it does in the treatment of heart failure with reduced ejection fraction,” said John McMurray, M.D., Professor of Medical Cardiology at University of Glasgow and PARAGON-HF Executive Committee Co-Chair. “Around half of all heart failure patients, some 13 million people worldwide, are estimated to suffer from HFpEF, and there is currently no approved treatment. Safety and tolerability were consistent with previously reported sacubitril/valsartan data. The trial narrowly missed statistical significance for its composite primary endpoint of reducing cardiovascular death and total heart failure hospitalizations.
![paragon trial paragon trial](https://i2.wp.com/macsoftware.org/wp-content/uploads/2020/09/Paragon-NTFS-Crack.png)
Totality of evidence suggests potential clinically important benefit results will be presented in September at the ESC Congress 2019, the annual meeting of the European Society of Cardiology (ESC).PARAGON study narrowly misses statistical significance on the primary endpoint overall safety profile confirmed.
#Paragon trial update#
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)